Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT01409135 Completed - Neoplasms Clinical Trials

A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4

Start date: July 11, 2011
Phase: Phase 1
Study type: Interventional

A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in subjects with malignant solid tumors that express Nectin-4.

NCT ID: NCT01407380 Completed - Malignancies Clinical Trials

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Start date: June 2011
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical effects of orally administered PWT33597 mesylate in subjects with advanced malignancies.

NCT ID: NCT01404728 Completed - Malignancies Clinical Trials

Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

Start date: January 8, 2013
Phase: N/A
Study type: Observational

This study evaluates the effects of treatment with a vaginal dilator to reduce vaginal stenosis in women receiving pelvic radiation therapy for pelvic malignancies.

NCT ID: NCT01404390 Completed - Neoplasms Clinical Trials

Japanese BAY80-6946 Monotherapy Phase I Study

Start date: August 18, 2011
Phase: Phase 1
Study type: Interventional

This study will be conducted as an open label, single centre, Phase I study of PI3K (phosphatidyl inositol 3 kinase) inhibitor BAY80-6946 in Japanese patients with advanced or refractory solid tumours. The eligible subjects will be dosed intravenously at Day 1, Day 8 and Day 15 with three weeks on and one week off in each treatment cycle.

NCT ID: NCT01403974 Completed - Neoplasms Clinical Trials

Phase I Trial of BI 836845 for Various Solid Cancer

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This study is a phase I, open-label, dose escalation trial to determine the maximum tolerated dose (MTD) or the relevant biological dose (RBD) in the absence if a MTD of a new drug BI 836845 which blocks the insulin-like growth factor (IGF) pathway believed to be involved in cancer growth. BI 836845 will be administered for the very first time into cancer patients. The study will also look at the overall safety of the drug, and examine the drug levels in the body at specific timepoints during the trial (pharmacokinetic profile); the effect the drug may have on tumours will also be examined (pharmacodynamics).

NCT ID: NCT01398306 Completed - Clinical trials for Neuroendocrine Tumors

Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

BANN
Start date: July 2011
Phase:
Study type: Observational

The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.

NCT ID: NCT01395056 Completed - Breast Neoplasms Clinical Trials

Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

DCCIK
Start date: July 2011
Phase: N/A
Study type: Observational

To access the effectiveness of cyclophosphamide combined thiotepa and carboplatin chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients

NCT ID: NCT01394991 Completed - Neoplasms Clinical Trials

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Start date: January 2006
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the safety of epoetin alfa in patients with cancer who have chemotherapy-related anemia.

NCT ID: NCT01394016 Completed - Advanced Cancer Clinical Trials

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Start date: December 7, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine a safe dose of LY2835219 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2835219 in this population. Efficacy measures will be used to assess the activity of LY2835219 in this population.

NCT ID: NCT01393990 Completed - Advanced Cancer Clinical Trials

A Study of LY2228820 in Participants With Advanced Cancer

Start date: September 4, 2008
Phase: Phase 1
Study type: Interventional

The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.